Last updated on November 2019

Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Subjects With B-cell Malignancies

Brief description of study

This study is evaluating the safety and preliminary efficacy of BGB-3111 in combination with BGB-A317 in subjects with B-cell lymphoid malignancies.

Clinical Study Identifier: NCT02795182

Find a site near you

Start Over

Epworth Healthcare

Richmond, Australia
  Connect »

Peter MacCallum Cancer Centre

Melbourne, Australia
  Connect »

Monash Hospital

Clayton, Australia
  Connect »